4
Changes in Ownership
Ensysce Biosciences, Inc. Filed Acc 0001493152-22-005444
Options or other derivatives
- Chief Commercial Officer acquired 50,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Birkett Kevin Geoffrey Chief Commercial Officer | 2022-02-17 | Grant or award · Stock Option | +50,000 | 50,000 | D | ||
Loading xslF345X03/ownership.xml…